한빛사논문
- 조회1,481
Abstract
Zeinab Hosseinidoust1,2, Babak Mostaghaci1, Oncay Yasa1, Byung-Wook Park1, Ajay Vikram Singh1, Metin Sitti*
Physical Intelligence Department, Max Planck Institute for Intelligent Systems, Stuttgart 70569, Germany
*Corresponding author.
1Equally contributing first authors.
2Current affiliation: Department of Chemical Engineering, McMaster University, Hamilton, ON, Canada.
Abstract
The use of bacterial cells as agents of medical therapy has a long history. Research that was ignited over a century ago with the accidental infection of cancer patients has matured into a platform technology that offers the promise of opening up new potential frontiers in medical treatment. Bacterial cells exhibit unique characteristics that make them well-suited as smart drug delivery agents. Our ability to genetically manipulate the molecular machinery of these cells enables the customization of their therapeutic action as well as its precise tuning and spatio-temporal control, allowing for the design of unique, complex therapeutic functions, unmatched by current drug delivery systems. Early results have been promising, but there are still many important challenges that must be addressed. We present a review of promises and challenges of employing bioengineered bacteria in drug delivery systems and introduce the biohybrid design concept as a new additional paradigm in bacteria-based drug delivery.
Keywords
Bacteria; Engineered; Biohybrid; Microrobotics; Synthetic biology; Gene therapy; Tumor targeting; Cell therapy; Microbial factories; Bactofection
논문정보
- Review Paper
- 2016년 09월 (BRIC 등록일 2016-10-04)
- 국외 연구진
- 바이오·의료융합 > 바이오센싱 및 나노바이오물질
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
